ABBOTT LAUNCHES MOLECULAR POINT-OF-CARE TEST TO DETECT NOVEL CORONAVIRUS IN AS LITTLE AS FIVE MINUTES
- The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines
- Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed most
- ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings
- Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day
- This is the company's second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month
https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-19-in-as-little-as-5-minutes.html
Recent TOMDF News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/17/2023 12:29:32 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM